Kostyantyn Krysan

4.8k citations
60 papers · 2.5k indexed · h-index 29

Kostyantyn Krysan

58 papers receiving 2.4k citations

Peers

Kostyantyn Krysan
Comparison fields: 5 of 111
  • Cancer Research 637
  • Pharmacology 711
  • Oncology 945
  • Immunology 453
  • Molecular Biology 1.1k
Replace Hiroyuki Achiwa with:
Hiroyuki Achiwa Japan
Jason R. Mann United States
Tonya C. Walser United States
Kuen‐Feng Chen Taiwan
C Paraskeva United Kingdom
Xiangsheng Zuo United States
Vincent C. Daniel United States
Michele Yip-Schneider United States
R J Coffey United States
Soner Altiok United States
Kostyantyn Krysan relative to Hiroyuki Achiwa Japan Hiroyuki Achiwa's profile →
Citations per field
00.5×10×15.6×
Hiroyuki Achiwa · 1×
Citations per year

Countries citing papers authored by Kostyantyn Krysan

Since Specialization
Citations

This map shows the geographic impact of Kostyantyn Krysan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kostyantyn Krysan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kostyantyn Krysan more than expected).

Fields of papers citing papers by Kostyantyn Krysan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kostyantyn Krysan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kostyantyn Krysan. The network helps show where Kostyantyn Krysan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kostyantyn Krysan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kostyantyn Krysan Line = papers co-authored together Kostyantyn Krysan links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20242
2 20246
3 202164
4 202115
5 202076
6 20192
7 201957
8 201811
9 20162
10 20163
11 20161
12 201436
13 20144
14 201331
15 200841
16 200846
17 200668
18 200449
19 200474
20 2002216

About Kostyantyn Krysan

Kostyantyn Krysan is a scholar working on Oncology, Pharmacology and Cancer Research, having authored 60 papers that have together received 2.5k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (19 papers), Cancer Immunotherapy and Biomarkers (12 papers), Estrogen and related hormone effects (10 papers), Immunotherapy and Immune Responses (9 papers), Cytokine Signaling Pathways and Interactions (8 papers), Epigenetics and DNA Methylation (6 papers), Cancer, Stress, Anesthesia, and Immune Response (6 papers) and Immune cells in cancer (6 papers). The work is most often cited by research in Cancer Research (637 citations), Pharmacology (711 citations) and Oncology (945 citations). Kostyantyn Krysan has collaborated with scholars based in United States, Ukraine and United Kingdom. Frequent co-authors include Steven M. Dubinett, Sherven Sharma, Mariam Dohadwala, Karen L. Reckamp, Mehis Pǒld, Harnisha Dalwadi, Ying Lin, Jie Luo, Raj K. Batra and Nathalie Heuzé‐Vourc'h. Their work appears in journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026